Starling Oncology
STLN

Starling Oncology (STLN) analyst forecast and price target

Analyst forecast

Buy

Consensus of 5 analyst ratings

Buy
5
Hold
0
Sell
0

Recent analyst ratings

FirmActionRatingPrice targetDate
NeedhamMaintainedBuy$9.00 from $7.00Oct 14, 2026
BTIGMaintainedBuy$9.00 from $8.00Jul 9, 2026
Lake StreetInitiated CoverageBuy$10.00Jul 6, 2026
NeedhamMaintainedBuy$7.00 from $5.00Jun 17, 2026
BTIGMaintainedBuy$8.00 from $7.00Jun 8, 2026
NeedhamMaintainedBuy$5.00Mar 13, 2026
B. Riley SecuritiesMaintainedBuy$8.00 from $6.00Mar 13, 2026
BTIGMaintainedBuy$7.00Mar 9, 2026
NeedhamMaintainedBuy$5.00Mar 9, 2026
NeedhamInitiated CoverageBuy$5.00Nov 25, 2025
BTIGMaintainedBuy$7.00Oct 21, 2025
B. Riley SecuritiesInitiated CoverageBuy$6.00Jul 16, 2025
JefferiesInitiated CoverageBuy$2.50Feb 26, 2024
GuggenheimMaintainedBuy$2.00 from $3.00Jun 16, 2023
GuggenheimMaintainedNeutral$3.00 from $6.00Mar 20, 2023

Frequently asked questions

  • Is STLN a buy, sell, or hold?

    Analysts covering Starling Oncology currently average a Buy rating: 5 buy, 0 hold and 0 sell, from 5 analysts. Ratings reflect analyst opinion, not investment advice.

  • What is the latest analyst rating on STLN?

    On Oct 14, 2026, Needham maintained Starling Oncology at Buy with a price target of $9.00.

Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.